Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Immunotherapy Regimens May Expand Use of Neoadjuvant Therapy in MIBC

April 21st 2020

Although the standard of care for muscle-invasive bladder cancer is well established, not enough patients are being treated with curative intent.

Nivolumab Plus Cabozantinib Improves OS in CheckMate-9ER Frontline RCC Trial

April 20th 2020

Nivolumab combined with cabozantinib improved overall survival and progression-free survival compared with sunitinib in patients with previously untreated advanced renal cell carcinoma.

Sonpavde Navigates Newfound GU Cancer Treatment Considerations Amid COVID-19 Crisis

April 16th 2020

Guru P. Sonpavde, MD sheds light on how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, perioperative surgical concerns for patients at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.

FDA Approves Mitomycin Gel for Urothelial Cancer

April 16th 2020

The FDA has approved mitomycin gel (Jelmyto) as the first therapy to treat low-grade upper tract urothelial cancer.

Dr. Joshi on Rationale for Durvalumab/RT Combo in Localized Urothelial Carcinoma

April 15th 2020

Monika Joshi, MD, discusses the rationale for using durvalumab in combination with radiation therapy in patients with localized urothelial carcinoma.

Other Trials of Interest in Renal Cancers

April 14th 2020

Promising Second-Line Therapies for mRCC

April 14th 2020

Progress in First-Line mRCC

April 14th 2020

Combination Therapies to Overcome Resistance in mRCC

April 14th 2020

VEGF TKI Therapy After I/O in mRCC

April 14th 2020

Second-Line Therapy After I/O in mRCC

April 14th 2020

mRCC: Resistance to VEGF and I/O

April 14th 2020

IMDC Criteria and Targeted Therapy in mRCC

April 14th 2020

VEGF-TKI Therapy in First-Line mRCC

April 14th 2020

SBRT in Combination With Ipilimumab/Nivolumab in mRCC

April 14th 2020

Ipilimumab/Nivolumab for Favorable-Risk mRCC

April 14th 2020

iRECIST Criteria and First-Line Treatment of mRCC

April 14th 2020

Ipilimumab/Nivolumab in First-Line mRCC

April 14th 2020

Cytoreductive Nephrectomy After I/O in mRCC

April 14th 2020

Cytoreductive Nephrectomy in mRCC: Current Data

April 14th 2020